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MUC4 is a large, heavily glycosylated transmembrane mucin, that is implicated in the pathogenesis of various types of cancers. To
date, no extensive study has been done to check the expression and functional significance of MUC4 in different types of gastric
adenocarcinomas. Here, we report the expression profile of MUC4 in gastric adenocarcinomas and its function in poorly
differentiated gastric non-signet ring cell carcinoma (non-SRCC) type cells. Immunohistochemical analysis using tissue microarray
(TMA) showed a significant difference in MUC4 expression between normal adjacent (n¼45) and gastric adenocarcinoma (n¼83;
Po0.001). MUC4 expression was not associated with tumour type, stage or with the degree of differentiation. To gain further insight
into the significance of MUC4 expression in gastric non-SRCC cells, MUC4 was ectopically expressed in AGS, a poorly differentiated
gastric non-signet ring cell line. The MUC4 overexpressing cells (AGS-MUC4) showed a significant increase (Po0.005) in cell motility
and a decrease in cellular aggregation as compared with the vector-transfected cells. Furthermore, in vivo tumorigenicity analysis
revealed that animals transplanted with the MUC4 overexpressing cells (AGS-MUC4) had a greater incidence of tumours (83%) in
comparison to empty vector control (17%). In addition, the expression of MUC4 resulted in enhanced expression of total cellular
ErbB2 and phosphorylated ErbB2. In conclusion, our results showed that MUC4 is overexpressed in gastric adenocarcinoma tissues,
and that it has a role in promoting aggressive properties in poorly differentiated gastric non-SRCC cells through the activation of the
ErbB2 oncoprotein.
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Gastric cancer is the fourth most commonly found cancer
worldwide and more than 90% of gastric cancers are adenocarci-
nomas (Correa et al, 2004). According to recent statistical
information, in the United States, 21500 new gastric cancer cases
are estimated for the year 2008 (Jemal et al, 2008). Despite
advances in diagnostic techniques such as imaging, esophago-
gastroduodenoscopy, magnetic resonance imaging and dual-phase
spiral computer tomography, early diagnosis of gastric adeno-
carcinoma is still a diagnostic problem for clinicians. An early
detection with accurate diagnosis and effective surgical or
endoscopic treatment can result in a better prognosis.
Gastric adenocarcinoma is classified into intestinal and diffuse
type of adenocarcinomas (Lauren, 1965). Morphologically, the
intestinal-type gastric adenocarcinoma has well-defined glands
with epithelial lining and diffuse-type gastric adenocarcinoma,
which mainly consists of scattered individual cells or clusters of
cells. It has been shown that the prevalence of poorly differentiated
gastric carcinomas is higher than well differentiated gastric cancers
(Nakamura et al, 1999).
Deregulation of mucins has been shown to be critical in a
number of gastro-intestinal malignancies including gastric cancer.
Normal gastric epithelial cells express a variety of mucins and have
different functions, such as protection against mechanical and
infectious insults, lubrication and acid resistance (Tasman-Jones,
1985; Hollingsworth and Swanson, 2004). Various reports have
shown that altered mucin carbohydrate and peptide residues of
mucins may be used as molecular markers of an increased risk of
malignant transformation (Girling et al, 1989; Hakomori, 1989;
Merlo et al, 1989; Ho et al, 1993; Springer et al, 1995; Llinares et al,
2004). Recent studies have provided strong evidences, which
potentiate the role of mucins in the pathogenesis of various
malignancies (Li et al, 2003; Yin et al, 2003; Singh et al, 2004). In
gastric adenocarcinoma, mucin expression pattern is heteroge-
neous. Mucins in gastric carcinoma include normal mucins of
stomach like MUC1, MUC5AC, MUC6 and de novo expression of
the intestinal mucins MUC2 (Carrato et al, 1994; Ho et al, 1995; Received 9 June 2008; revised 31 July 2008; accepted 4 August 2008
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sSakamoto et al, 1997; Baldus et al, 1998; Reis et al, 1998, 2000;
Utsunomiya et al, 1998).
MUC4, is a membrane-bound mucin and has a significant
role in different cancers including pancreatic and breast
cancers (Singh et al, 2004). MUC4 expression is also associated
with the poor prognosis for pancreatic, lung and bile duct
cancer patients. Overexpression of MUC4 in pancreatic cancer
potentiates pancreatic tumour cell proliferation, survival and
invasive properties and also interferes with its interaction to
extracellular matrix proteins (Chaturvedi et al, 2007). MUC4
also interacts with ErbB2, a growth factor receptor, stabilizes
it at the cell surface and hence has an important function in
modulating ErbB2-mediated oncogenic signaling in pancreatic
cancer cells (Chaturvedi et al, 2008). The importance of MUC4
for activation of ErbB2 in poorly differentiated gastric SRCC
has been reported (Yokoyama et al, 2007). However, to date there
is a lack of knowledge about the functional significance of
MUC4 in poorly differentiated gastric cancers other than the
SRCC subtypes.
Realizing the importance of MUC4 in different malignancies,
we prompted to investigate the expression pattern of MUC4 in
different gastric adenocarcinomas. In this study, we have shown
that MUC4 is overexpressed in the gastric cancer and its
expression pattern does not correlate with type, differentiation
or stage of cancer. In consideration of MUC4 expression in poorly
differentiated gastric non-SRCC cells and its role in the activation
of ErbB2 in gastric SRCC cells, we did in vitro and in vivo studies
to check the significance of MUC4 in non-SRCC cells. Here, we
have shown that MUC4 overexpression in poorly differentiated
AGS, gastric cancer cells, increases its aggressive cancer property
in both in vitro and in vivo experiments. In addition, over-
expression of MUC4 in AGS, gastric cancer cells, increases both
total and phosphorylated form of ErbB2.
MATERIALS AND METHODS
Cell culture and transfection
AGS, MKN45 and KATOIII cell lines were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
AGS cells were grown in Ham’s F/12 supplemented with 10% fetal
bovine serum, MKN45 cells were grown in RPMI-1640 supple-
mented with 10% fetal bovine serum and KATOIII cells were
grown in RPMI-1640 supplemented with 20% fetal bovine serum.
In all the media 100gml
 1 penicillin and streptomycin were
added. Cell lines were maintained in a 371C incubator with 5% CO2
and in a humidified atmosphere. For the overexpression of MUC4
an engineered MUC4 construct (MUC4minigene) was made, which
contains 10% of the tandem repeat sequence. The MUC4minigene
construct was stably transfected in AGS cell line for constitutive
expression of MUC4. For control, cells were transfected with empty
vector (pSecTagC). Stable clones were then selected in a medium
containing Zeocin (400mgml
 1). The Zeocin-resistant colonies
were isolated by the ring cloning method and maintained in the
medium supplemented with Zeocin. The medium was replaced
with a complete medium without antibiotic supplement for at least
5 days before any analysis.
Immunoblot assay
The AGS, MKN45 and KATOIII cell lines were processed for
extraction of whole cell protein and using standard protocol
western blotting was carried out. The cells were washed two times
with phosphate-buffered saline (PBS) and scraped in radio-
immunoprecipitation assay buffer (50mM Tris, 5mM ethylenedia-
minetetraacetic acid (EDTA), 150mM NaCl, 0.25% sodium
deoxycholate, 1% NP40 pH 7.5), supplemented with protease
inhibitor mixture (Roche Diagnostics, Mannheim, Germany) and
kept at 41C for at least 30min. Cell lysates were passed through the
28G tuberculin needle or alternatively subjected to one freeze thaw
cycle to facilitate the disruption of the cell membranes. Cell lysates
were centrifuged at 14000r.p.m. for 20min at 41C and super-
natants were collected. Using a BIO-RAD DC protein estimation
kit the samples were quantified. Owing to the large size of MUC4,
the protein samples were resolved by electrophoresis on a 2%
SDS-agarose gel under reducing condition. Resolved proteins
were transferred onto the polyvinylidene difluorided membrane.
For MUC4 detection anti-MUC4 mouse monoclonal antibody
(8G7) was used. For the detection of total ErbB2/HER2 and
phosphorylated ErbB2/HER2, anti-HER2 rabbit polyclonal (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and pY1248-HER2
(Upstate Biotech, Lake Placid, NY, USA) antibodies were used
respectively. Secondary antibodies consisted of horseradish
peroxidase-conjugated anti-mouse/anti-rabbit, which were used
for the immunodetection. The blots were processed with ECL
chemiluminescence kit (Amersham Biosciences, Piscataway, NJ,
USA), and the signal was detected by exposing the processed blots
to X-ray films (Biomax Films, Kodak, NY, USA).
Confocal immunofluorescence microscopy
Cells were grown at low density on sterile coverslips for 20h. After
washing with 0.1 M HEPES containing Hanks buffer, the cells were
fixed in ice-cold methanol at  201C for 2min. Nonspecific
blocking was done by using 10% goat serum containing 0.05%
Tween-20 for 30min, followed by incubation with anti-MUC4
monoclonal antibody (8G7) in PBS for 90min at room tempera-
ture. Cells were washed 3–4 times with PBS containing 0.05%
Tween-20 (PBS-T) and then incubated with FITC-conjugated goat
anti-mouse secondary antibodies for 60min. The cells were
counterstained with propidium iodide. Finally slides were washed
two times with PBS and mounted on glass slides in antifade
Vectashield mounting medium (Vector Laboratories, Burlingame,
CA, USA). The slides were observed under a ZEISS confocal laser-
scanning microscope, and photographs were captured digitally
using 510 software.
Tissue microarrays and immunohistochemistry
To have more number of sample sizes, tissue microarray slides
were ordered from two different companies. The AccuMax TM
(cat. no. A209) has total of 50 different cancer cases and four non-
neoplastic tissues (one corresponding, three non-corresponding).
The TMA slide had two spots for each cancer tissue and one spot
for each non-neoplastic tissue. Tissue microarray slide from US
Biomax Inc. (ST801) had a total of 40 individual cases and each
normal adjacent tissue is placed next to its matched cancer tissue.
As per recommendations of the manufacturer, before conducting
immunohistochemistry, the slides were baked at 601C for 2h. Then
slides were deparaffinized by using EzDewax (Bio Genex, CA, USA)
for 30min. Sections were hydrated through graded alcohol and
endogenous peroxidase activity was quenched by incubating the
sections in 0.3% H2O2 in methanol for 30min. After washing the
slides in PBS (5min 2), antigen retrieval was done by heating the
slides in citrate buffer (0.01 M, pH 6.0) at 801C for 20min. After
heating the samples were allowed to cool for 15–20min in room
temperature. This was followed by washing with PBS (5min 2).
Nonspecific binding was blocked by incubating the sections with
2.5% horse serum for 30min (Impress reagent Kit,Vector).This
was followed by washing with PBS (5min 2). Sections were then
incubated with anti-MUC4 monoclonal antibody (1:2500) at 41C
overnight. Then slides were washed and incubated with secondary
antibody (peroxidase labeled Universal anti-mouse/anti-rabbit IgG
(Vector, CA)) for 30min. Then sections were washed with PBS
followed by treatment with DAB reagents (0.2mgml
 1) and
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sincubated for 10min. After washing with distilled water, counter
staining was done by using haematoxylin (Vector, CA, USA). After
washing in tap water, sections were dehydrated in graded alcohol
and after air drying the slides were mounted in permount
permanent mounting media (Fisher Scientific, Fair Lawn, NJ,
USA). All slides were observed under Nikon E400 light microscope
and representative photographs were taken.
Motility assay
For motility assay, 1 10
6 cells were plated on the top chamber of
a non-coated polyethylene teraphthalate membrane (six-well inset,
pore size 8mm; Becton Dickinson, Franklin Lakes, NJ, USA). The
bottom chamber contained 1.0ml DMEM supplemented with 10%
fetal bovine serum. The cells were incubated for 24h, and the cells
that did not migrate through the pores in the membrane were
removed by scraping the membrane with a cotton swab. Cells that
transversed the membrane were stained with Diff-Quick cell
staining kit (Dade Behring Inc., Newark, DE, USA). Cells in 10
random fields of view at  100 magnifications were counted and
expressed as the average number of cells/field of view. Three
independent experiments were done in each case. These data were
represented as the average of the three independent experiments
with the s.d. of the average indicated.
Aggregation assay
Cells were tested for their ability to aggregate in hanging drop
suspension cultures. Cells were trypsinized in the presence of
EDTA, washed two times in PBS, and resuspended at 2.5 10
5
cellsml
 1 in the appropriate medium containing 10% fetal bovine
serum. Drops (20ml each) of medium, containing 5000 cells/drop,
were pipetted onto the inner surface of the lid of a Petri dish. The
lid was then placed on the Petri dish so that the drops were
hanging from the lid with the cells suspended within them. To
eliminate evaporation, 8ml of serum-free culture medium were
placed in the bottom of the Petri dish. After overnight incubation
at 371C, the lid of the Petri dish was inverted and photographed
using a Nikon TS100 inverted tissue culture microscope at  40
magnifications.
In vivo tumorigenicity assay
To test the tumorigenic capacity, the MUC4-transfected AGS
cells along with the control cells were harvested from subconfluent
cultures by a brief exposure to 0.25% trypsin and 0.02%
EDTA. After neutralising the effect of trypsin with 10% fetal
bovine serum, the cells were washed once in PBS. Cell viability and
number were determined by trypan blue staining using a
hemocytometer. Cells were resuspended in a normal saline
solution at a concentration of 25 10
6 cellsml
 1. Single-cell
suspensions of 490% viability was used for the injections.
Immunodeficient mice were purchased from the Animal Produc-
tion Area of the National Cancer Institute-Frederick Cancer
Research and Development Center (Frederick, MD, USA).
The mice were housed in specific pathogen-free conditions and
fed sterile water and food ad libitum. The mice were treated
in accordance with the Institutional Animal Care and Use
Committee guidelines. 5 10
6 viable MUC4-transfected AGS-
MUC4 cells, resuspended in a normal saline solution, were injected
subcutaneously in six immunodeficient mice. Empty vector
transfected cells (AGS-pSecTagC) were used as a control (n¼6).
The animals were monitored two times weekly for tumour
formation up to 4 months after inoculation. A palpable mass was
observed at the inoculation site at around 80 days of post-
injection, followed by rapid growth of the tumour. All mice were
killed on day 120 after implantation, and the incidence of tumour
was determined.
Statistical analysis
Subjects with normal or adenocarcinoma or signet ring cell
carcinoma were included in the analysis. The distribution of type,
grade and stage was compared between positive and negative
intensity groups using a w
2 test or Fisher’s Exact test where
appropriate. Tumour incidence was compared between groups
using Fisher’s Exact test.
RESULTS
Immunohistochemical analysis of MUC4 expression in
gastric cancer tissues
As a first step toward studying the role of MUC4 in gastric cancer,
we did immunohistochemical analysis of MUC4 expression on
TMA samples of gastric adenocarcinoma and normal adjacent
area. MUC4 staining showed a diffuse staining pattern (membrane/
cytoplasmic) in most of the tissue sections. Representative pictures
of the stained gastric tumour tissue sections are presented in
Figure 1. Statistical analysis was conducted to determine the
association of MUC4 expression pattern with cancer type,
differentiation and stage of the tumour (Tables 1 and 2). Out of
a total of 128 tissue spots, we found that the proportion of MUC4-
positive staining is lower for normal adjacent spots (n¼45, 9%)
compared with patients with adenocarcinoma (n¼58, 43%) and
signet ring cell carcinoma (n¼25, 32%) (Po0.001). However, no
significant difference was found in MUC4 expression between
adenocarcinomas and signet ring cell carcinomas (P¼0.34).
Furthermore, no significant correlation was found between tumour
differentiation and MUC4 expression for all cancer patients
combined (P¼0.34) (Table 1). MUC4 expression pattern did not
significantly correlate with the stage of tumour, both individually
(P¼0.16) or in groups, that is, I/II (early stage) and III/IV (late
stage) (P¼0.21) (Table 2).
Expression of MUC4 in different gastric cancer cell lines
Using immunoblot assay, MUC4 expression was checked in three
different types of gastric adenocarcinoma cell lines (AGS, MKN45
and KATOIII). MUC4 expression was detected in KATOIII (SRCC)
but was undetectable in AGS and MKN45 cell lines (Figure 2). To
further analyse the role of MUC4 in the aggressiveness of non-
signet ring cell type poorly differentiated gastric adenocarcinomas,
MUC4 was ectopically expressed in AGS gastric cancer cell line
(using an engineered MUC4 cDNA construct, MUC4minigene
(Moniaux et al, 2007)). The MUC4minigene’s deduced protein
(320kDa) is analogous to that of wild-type MUC4 protein
(930kDa) (Moniaux et al, 2007). Western blot analysis (Figure 3)
and confocal study showed the overexpression of MUC4 in selected
clones transfected with MUC4 construct in comparison to empty
vector transfected clones (Figure 3). Furthermore, confocal
analysis showed the membrane localisation of MUC4 in AGS-
MUC4 clones.
MUC4 overexpression increases cell motility in AGS gastric
cancer cells
The aggressiveness of a malignant cell depends on its potential to
invade the ECM and its ability to metastasize to distant sites.
Different studies have shown that the invasive and metastasis
potential of cancer cells are strongly related to a variety of
phenotypic characteristics. Among these characteristics, motility
of cells highly influences the metastatic property of cells
(Yamaguchi et al, 2005). As the MUC4 overexpression is associated
with an increased motility of pancreatic cancer cells, we examined
whether the MUC4 overexpression in gastric cancer is associated
with an increase in cell motility or not. Cell motility was
MUC4 in gastric cancer
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sdetermined on top of the uncoated porous membrane. The number
of MUC4 overexpressing AGS gastric cancer cells (AGS-MUC4)
migrated to the lower surface of the porous membrane was
significantly high (Po0.005) than that of the vector control (AGS-
vector) cells (Figure 4A).
Overexpression of MUC4 decreases aggregation property
of AGS gastric cancer cells
Like cell motility, aggregation property of cells is also a critical
factor, which affects the metastasis property of tumour cells.
The aggregation property is usually deregulated in the tumour
cells because of alteration in the expression of different cell
surface molecules (Sommers, 1996; Komatsu et al, 1997;
Truant et al, 2003). Therefore, to test the effect of MUC4
overexpression on adhesiveness of AGS cells, we used the
aggregation assay described in Materials and methods. MUC4
overexpression showed a decrease in aggregation of AGS-MUC4-
transfected cells in comparison to vector-transfected control cells
(Figure 4B).
Overexpression of MUC4 enhances tumorigenicity of AGS
gastric cancer cells in nude mice
To investigate the role of MUC4 on tumorigenic property of gastric
cancer cells, AGS-MUC4 and AGS-vector cells, were injected
subcutaneously into immune deficient nude mice. 5 10
6 cells
were injected and a palpable mass was first noticed at the eightieth
day of post-inoculation and continued to grow up to 120 days.
Among the six mice inoculated with AGS-MUC4 cells, incidence of
tumour was observed in five mice (83%), whereas only one mouse
had a tumour among the six mice inoculated with AGS-vector cells
(17%). Further, statistical analysis showed that this difference in
the incidence of the tumour between the two groups is marginally
significant (P¼0.08) (Table 3).
Normal Adenocarcinoma
×10 ×10
×40 ×40
AB
Figure 1 Immunohistochemical analysis of gastric tissues for MUC4 expression by using gastric cancer tissue microarray (TMA) slides. Tissue sections
were stained for MUC4 using anti-MUC4 monoclonal antibody followed by biotinylated secondary antibody incubation and streptavidin peroxidase 3,30-
diaminobenzidine-chromogen detection. All the sections were examined under microscope and the immunoreactivity was judged by dark brown staining.
(A) Representative picture of stained gastric normal adjacent tissues showing no visible MUC4 staining. (B) Representative picture of gastric
adenocarcinoma tissues showing diffused MUC4 staining. All sections were counter stained with haematoxylin. In all the top panels, original magnification is
 10 and in bottom panels, original magnification is  40.
Table 1 Association of MUC4 expression pattern with types and grades
of gastric cancer
Tissues
MUC4-negative
N (%)
MUC4-positive
N (%) P-value
Types
Normal 41 (91%) 4 (9%) Po0.001
Adenocarcinoma 33 (57%) 25 (43%)
SRCC 17 (68%) 8 (32%)
Differentiation
Moderate 9 (53%) 8 (47%)
Poor 30 (58%) 22 (42%) P¼0.34
Not 4 (100%) 0 (0%)
Well 7 (70%) 3 (30%)
Table 2 Association of MUC4 expression pattern with stages of gastric
cancer
Cancer stage
MUC4-negative
N¼28
MUC4-positive
N¼19 P-value
I 11 (58%) 8 (42%) 0.16***
II 6 (100%) 0 (0%)
III 9 (50%) 9 (50%)
IV 2 (50%) 2 (50%)
***Fisher’s Exact test. Information regarding the tumour stage was not available for all
the spots.
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sOverexpression of MUC4 activates ErbB2 oncoprotein in
AGS gastric cancer cells
shRNA-mediated knock-down of MUC4 in pancreatic cancer cells
showed a decrease in the total levels and phosphorylated form of
ErbB2 protein (at Tyr
1248) and was shown that overexpression of
MUC4 plays a crucial role in stabilising ErbB2 (Chaturvedi
et al, 2007, 2008). Other studies have shown that in SRCC type
gastric cancer cells, MUC4 is required for the activation of ErbB2
(Yokoyama et al, 2007). On the basis of these earlier observations,
we wanted to determine whether MUC4 exerts its function through
regulating ErbB2 expression and activation in AGS-MUC4 gastric
cancer cells. The expression of total and active form of ErbB2 was
measured by western blot analysis. Cell lysate of AGS-MUC4
showed increased level of total and phosphorylated (at Tyr
1248)
ErbB2 protein compared with the control AGS-vector cell lysate
(Figure 5).
DISCUSSION
MUC4 is one of the most widely studied membrane-bound mucins
having a significant function in the pathogenesis of several cancers
(Shibahara et al, 2004; Singh et al, 2004). The aberrant expression
of MUC4 has been reported in different types of carcinomas
(Andrianifahanana et al, 2001; Llinares et al, 2004; Weed et al,
2004). It has been shown that MUC4 expression correlates with
cancer progression (Swartz et al, 2002; Park et al, 2003). In this
study, we showed that MUC4 is overexpressed in gastric cancer
tissues as compared with normal adjacent tissues. Overexpression
of MUC4 was associated with an aggressive phenotype of gastric
cancer cells. MUC4 overexpression also increased the activation of
ErbB2 oncoprotein. Hence, our study provides for the first time,
the importance of MUC4 in gastric cancer and explains the
possible mechanism through which MUC4 can promote aggressive
property of poorly differentiated gastric non-SRCC cells.
In this study, we examined and compared the expression of
MUC4 in gastric cancer tissues. MUC4 showed a significant
overexpression in gastric cancer tissues compared with the normal
adjacent tissues. Similar findings showing the overexpression of
MUC4 in gastric adenocarcinoma has been reported earlier
(Lopez-Ferrer et al, 2000). MUC4 is known to be expressed in
the embryonic gastric tissues around 8 weeks of gestation (Buisine
et al, 2000). It has also been shown that many embryogenesis
phenomena like cell proliferation, lineage allocation, cell migration
and differentiation of cells are also seen during cancer progression.
Therefore, overexpression of MUC4 in adult gastric carcinoma
supports the concept of ‘fetal antigen’ expression during malignant
condition and indicates its possible role in gastric cancer
progression. Further, our statistical analysis showed that there is
no significant association between MUC4 expression with type,
grade of differentiation and stage of gastric cancer. This suggests
that MUC4 itself may not be a potential marker for early diagnosis
of gastric cancer. Previous studies performed regarding the role of
mucins as diagnostic and prognosis markers in gastric carcinoma
tissue showed contradictory results (Correa and Shiao, 1994; Byrd
et al, 1997). Therefore, for higher accuracy, many studies have
been done to evaluate the combined expression pattern of mucins
with other molecules such as E-cadherin with MUC1 expression
(Tanaka et al, 2003). Similarly, comparing the expression pattern
AGS
KATOIII
FG
MUC4
-Actin
MKN45
Figure 2 Western blot analysis of MUC4 expression in gastric cancer
cell lines. Total protein lysates from AGS, KATOIII and MKN45
gastric cancer cells were prepared. Protein lysate from FG (pancreatic
cancer cell line) cells was taken as a positive control. Protein lysates
were electrophoretically resolved on 2% agarose gel. Resolved proteins
were transferred onto PVDF membrane and probed with MUC4 MAb
(8G7) and detected using Amersham HRP-conjugated secondary antibody
and ECL kit. Immunoblot of b-actin, obtained from 10% SDS–PAGE/
Western, was used as an internal control to correct for the loading
variation.
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Figure 3 Expression of MUC4 in AGS and its derived sublines: AGS-vector (empty vector transfected) and AGS-MUC4 (MUC4-transfected) cells. (A)
Western blot analysis: total protein lysates were prepared from the subconfluent cells. A total of 20mg protein from cell extracts was electrophoretically
resolved on 2% Agarose gel. Resolved proteins were transferred onto PVDF membrane and probed with MUC4 MAb (8G7). Protein from FG (pancreatic
cancer cell line) cells was taken as a positive control. (B) Expression analysis of MUC4 using confocal microscopy: Cells were grown at a low density on
sterilised cover slips; after methanol fixation, slides were incubated with MUC4 MAb (8G7), followed by FITC-conjugated secondary antibody, and were
observed under a ZEISS confocal laser-scanning microscope (magnification,  630).
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strengthen the study and may potentiate the possible use of MUC4
as a diagnostic and prognostic marker for gastric adenocarcinomas.
Different studies have shown the functional role of MUC4 in
tumorigenicity and metastasis property of cancer cells (Singh et al,
2004; Chaturvedi et al, 2007). Recently, we have also shown that in
pancreatic cancer cells MUC4 interacts with ErbB2 and stabilizes
its localization on the cell membrane (Chaturvedi et al, 2008). In
another very recent study, it has been shown that MUC4 interacts
with ErbB2 in human gallbladder carcinoma and helps in the
activation of erbB2 (Miyahara et al, 2008).Till date, information
regarding the role of MUC4 in gastric cancer is very less, recently,
it has been shown that specifically in poorly differentiated type
gastric signet ring cell carcinoma cells, MUC4 is required for the
activation of ErbB2. Because MUC4 is expressed even in poorly
differentiated gastric non-SRCC cells, we therefore reasoned that
MUC4 might have a possible role in those kinds of cells. Here, we
report that out of the three poorly differentiated cells (KATOIII,
MKN45 and AGS), only KATOIII, which is a signet ring cell
carcinoma cell line, expresses MUC4.
Further, to check the actual role of MUC4 in non-SRCC type
poorly differentiated gastric cancer cells, MUC4 was ectopically
overexpressed in a gastric adenocarcinoma cell line (AGS), which
has an undetectable expression level of MUC4. In different in vitro
studies, we found that, MUC4 causes an increase in the motility of
AGS-MUC4 cells, and a decrease in the adhesive property of AGS-
MUC4 cells. This finding supports other studies where MUC4 has a
similar function in other cancers, such as pancreatic cancer (Singh
et al, 2004; Chaturvedi et al, 2007). The increase in cell motility
(Po0.05), which has a major role during the dynamic process
of tumour invasion and metastasis, may be a direct result of
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Figure 4 Phenotypic changes of AGS-MUC4 cells compared with AGS-vector cells. (A) Cell motility assay: MUC4 expression correlates with the cell
motility. Cells (1 10
6) were plated in the top chamber of noncoated polyethylene teraphthalate membranes and incubated for 20h. Cells that transversed
the membranes were stained with a Diff-Quick cell staining kit. The number of cells transversing the membrane was determined by averaging 10 random
fields of view at  100 and expressed as the average number of cells/field of view and is the average of two independent experiments. Mean±s.e.; n¼20;
*Po0.005. Cell motility was significantly (Po0.005) increased in MUC4-transfected AGS cells. (B) Aggregation assay: drops of medium (20ml each)
containing 500 cells/drop were pipetted onto the inner surface of the lid of a Petri dish. After overnight incubation at 371C, the lid of the Petri dish was
inverted and photographed using a Nikon TS100 inverted tissue culture microscope at  40 magnification. An increased cellular aggregation observed in
AGS-MUC4 cells.
Table 3 Incidence of tumours in animals injected with AGS-MUC4 and
AGS-pSecTagC cells
Name of the
group
Number of
animals injected
Number of animals
having tumour P-value
AGS-MUC4 6 5 (83%) P¼0.08***
AGS-Vector 6 1 (17%)
*** Fisher’s Exact test.
-Actin
pY1248-ErbB2
ErbB2
AGS-vector
AGS-MUC4
Figure 5 Effect of MUC4 expression on ErbB2 expression and
phosphorylation. (A) Western blot analysis: a total of 20mg of protein
from AGS-derived cell lines, were resolved by SDS-PAGE and transferred
to PVDF membrane and probed with antibodies against, ErbB2, Phospho-
tyr 1248 ErbB2, and b-actin. MUC4-transfected AGS cells showed an
increased level of total and phosphorylated ErbB2 in comparison to vector-
transfected cells.
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through an ErbB2-mediated pathway (Singh et al, 2007). During
cancer cell metastasis, cells remain loosely attached to the ECM or
to the other cells. This property is essential to make the cells more
migratory and to increase the invasiveness of cancer cells. In our
aggregation assay, we found that MUC4 overexpression in AGS
cell line, decreases its aggregation property, or in other words
enhances its metastatic property. This decreased adhesive property
among cells may be because of charge–charge repulsion on
account of the presence of negatively charged O-glycosidic chains
present in the central repetitive domain of MUC4 or owing to
disruption of integrin-mediated cell adhesion. Furthermore, the
high incidence of tumours in animals injected with AGS-MUC4
cells than animals inoculated with AGS-vector cells, indicate the
role of MUC4 in tumorigenicity of gastric cancer cells.
Decrease in cell death and increase in cell proliferation are two
major regulatory elements in enhancing the tumorigenicity of
cancer cells. Overexpression of ErbB2 oncoprotein has been shown
to correlate with tumour aggressiveness in various tumours (Hynes
and Lane, 2005). In gastric cancer, a correlation between ErbB2
gene amplification and prognosis of patients has been reported
(Nakajima et al, 1999; Lin et al, 2000). In this study, similar to our
previous report, we also observed an increase in total ErbB2 and
phosphorylated ErbB2 expression in MUC4 expressing AGS cells.
AGS, is a well studied poorly differentiated cell line (Barranco et al,
1983). The tumorigenicity of this cell line in animals has been
already reported (Barranco et al, 1983). Here, the increase in
tumorigenicity of AGS cells mediated by MUC4 may be on account
of the interaction of MUC4 with ErbB2 and further stabilisation
and activation of ErbB2-mediated oncogenic signaling.
In conclusion, our in vitro and in vivo studies showed a
significant role of MUC4 in promoting the aggressiveness and
tumorigenicity of poorly differentiated gastric non-SRCC cells. In
addition, we showed a possible mechanism through which MUC4
can increase the tumorigenicity property of poorly differentiated
gastric non-SRCC cells. Validation for MUC4 expression as a
prognostic marker requires further studies. A study on the
combined expression pattern of MUC4 and other molecules like
E-cadherin or other mucins may provide more accuracy and
specificity to use MUC4 as a diagnostic or prognostic marker for
gastric cancer. Our study also indicates that MUC4 can be targeted
for treatment of gastric cancer.
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